Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy

被引:4
|
作者
Jasmiad, Nurbadriah Binti [1 ]
Abd Ghani, Rohana Binti [1 ,2 ]
Agarwal, Renu [3 ]
Ismail, Zaliha Binti [4 ]
Abdullah, Azlindarita Aisyah Mohd [5 ,6 ]
Idorus, Mohd Yusri [7 ]
机构
[1] Univ Teknol MARA UiTM, Fac Med, Dept Internal Med, Sungai Buloh, Selangor Darul, Malaysia
[2] Univ Teknol MARA UiTM, Inst Pathol Lab & Forens Med I PPerForM, Sungai Buloh, Selangor Darul, Malaysia
[3] Int Med Univ, Sch Med, Dept Pharmacol & Therapeut, Kuala Lumpur, Malaysia
[4] Univ Teknol MARA UiTM, Fac Med, Dept Publ Hlth Med, Sungai Buloh, Selangor Darul, Malaysia
[5] MSU Med Ctr, Shah Alam, Selangor Darul, Malaysia
[6] Management & Sci Univ, MSU Clin Ctr Excellence, Shah Alam, Selangor Darul, Malaysia
[7] Univ Teknol MARA UiTM, Fac Med, Inst Med Mol Biotechnol IMMB, Sungai Buloh, Selangor Darul, Malaysia
关键词
Type 2 diabetes mellitus; Diabetic retinopathy; Tissue plasminogen activator (tPA); Plasminogen activator inhibitor-1 (PAI-1); INSULIN-RESISTANCE; OBESITY; PROTEINS; PARAMETERS; PAI-1;
D O I
10.1186/s12886-022-02550-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Diabetic retinopathy (DR) is a serious complication of longstanding type 2 diabetes mellitus (T2DM), a leading cause of blindness and visual disability in the world. The aim of this study is to compare the activity of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in tears and serum of patients with DR and those without DR. Method Among the T2DM patients enrolled in this study, 26 patients had DR (n = 26) while 29 were without DR (n = 29). The blood and tear samples were obtained from all participants. The level of PAI-1 and tPA were measured in both the serum and tears. Anthropometric measurements, HbA1c, renal and lipid profile were also obtained. Results Patients with DR had significantly longer disease duration and higher systolic blood pressure compared to those without DR. Serum PAI-1 level was significantly higher in patients with DR compared to those without DR, 32.72 (IQR 32.52) vs 21.37 (IQR 14.93) ng/mL, respectively (p < 0.05). However, tear PAI-1 were comparable in both groups. Serum and tear tPA levels in both groups were also comparable (p > 0.05). Among patients with DR, there were no significant correlations between tear and serum of both biomarkers. Patients without DR showed a moderate positive correlation between serum and tear tPA levels with a coefficient of 0.363, albeit no statistical significance. Patients with DR demonstrated a significant positive correlation between levels of tears PAI-1 and BMI (r = 0.555, p = 0.026). In the group without DR, there was a statistically significant positive correlation between serum level of PAI-1 with urine albumin creatinine ratio (UACR) (r = 0.501, p = 0.013). Conclusion The present study demonstrated a significantly greater serum PAI-1 levels in patients with DR compared to those without DR. No significant correlations between tears and serum PAI-1 and tPA were observed. Thus, the role of tear biomarkers remains relevant for further investigations.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Increased plasminogen activator inhibitor-1/tissue type plasminogen activator ratio in oral submucous fibrosis
    Yang, S-F
    Hsieh, Y-S
    Tsai, C-H
    Chen, Y-J
    Chang, Y-C
    ORAL DISEASES, 2007, 13 (02) : 234 - 238
  • [42] Plasminogen activator inhibitor-1 and Restenosis
    Garg, Nadish
    Fay, William P.
    CURRENT DRUG TARGETS, 2007, 8 (09) : 1003 - 1006
  • [43] Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms inn patients with chronic periodontitis
    Gurkan, Ali
    Emingil, Gulnur
    Saygan, Buket Han
    Cinarcik, Serhat
    Atilla, Gul
    Kose, Timur
    Berdeli, Afig
    JOURNAL OF PERIODONTOLOGY, 2007, 78 (07) : 1256 - 1263
  • [44] RELATIONSHIPS BETWEEN EUGLOBULIN CLOT LYSIS TIME AND THE PLASMA-LEVELS OF TISSUE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1
    URANO, T
    SAKAKIBARA, K
    RYDZEWSKI, A
    URANO, S
    TAKADA, Y
    TAKADA, A
    THROMBOSIS AND HAEMOSTASIS, 1990, 63 (01) : 82 - 86
  • [45] PLASMINOGEN-ACTIVATOR INHIBITOR-1(PAI-1) AND TISSUE-PLASMINOGEN ACTIVATOR PLASMINOGEN-ACTIVATOR INHIBITOR-1(TPA-PAI-1) IN IDDM - PROFILE BY COMPLICATIONS
    SUMINSKI, R
    DASILVA, S
    SMITH, M
    ERBEY, J
    DIABETES, 1994, 43 : A197 - A197
  • [46] A genome-wide scan for circulating levels of plasminogen activator inhibitor-1 and tissue plasminogen activator in the Framingham Heart Study
    O'Donnell, CJ
    Larson, MG
    Cupples, LA
    Feng, D
    Caunt, D
    D'Agostino, RB
    Myers, RH
    Tofler, GH
    CIRCULATION, 2000, 102 (18) : 257 - 257
  • [47] TISSUE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 LEVELS IN PATIENTS WITH NON-DISSOLVING PULMONARY THROMBOEMBOLISM
    MOSER, KM
    MITCHELL, MA
    MARSH, JJ
    BINDER, BR
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 96 - 96
  • [48] Gene-based Haplotypes at the plasminogen activator inhibitor-1 locus are associated with circulating plasminogen activator inhibitor-1 levels.
    Kathiresan, S
    Yang, Q
    Lochner, A
    Larson, MG
    Tofler, GH
    Gabriel, S
    O'Donnell, CJ
    CIRCULATION, 2004, 109 (07) : E77 - E77
  • [49] Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels
    Kathiresan, S
    Gabriel, SB
    Yang, Q
    Lochner, AL
    Larson, MG
    Levy, D
    Tofler, GH
    Hirschhorn, JN
    O'Donnell, CJ
    CIRCULATION, 2005, 112 (12) : 1728 - 1735
  • [50] Serum leptin and plasminogen activator inhibitor-1 levels in children on chronic dialysis
    Agras, Pinar Isik
    Baskin, Esra
    Cengiz, Nurcan
    Sezer, Siren
    Haberal, Aysegul
    Ozbek, Namik
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 182 - 182